A prototype, semi-automated, indigenous solid-target assembly has been developed to produce clinical grade ¹¹¹InCl₃ from ^natCd targets. Fluka Monte Carlo code was used to estimate the optimum proton energy range for ¹¹¹Cd(p,n)¹¹¹In production route and suitable decay time to get high specific-activity of ¹¹¹In. The radiochemical purification and separation have been optimized using column chromatography separation method. The quality of ¹¹¹InCl₃ has been established by radiolabeling of Pentetreotide yielding ¹¹¹In-Pentetreotide, in acceptable radiochemical purity (RCP), with expected biological efficacy in in-vitro and in-vivo models. Pre-clinical translation of ¹¹¹InCl₃ in formulation of ¹¹¹In-Pentetreotide adds support toward its use as a clinical grade radiochemical.